DUBLIN, Dec. 14, 2020 /PRNewswire/ -- Medtronic plc
(NYSE:MDT) announced today that Sean
Salmon, Executive Vice President and President, Diabetes
Operating Unit has been named Executive Vice President and
President, Cardiovascular Portfolio effective January 1. Salmon will also continue to lead the
Diabetes Operating Unit and continue to serve on the company's
Executive Committee. He succeeds Mike
Coyle, who will leave Medtronic effective December 31 to accept a CEO role of a publicly
traded company.
"We owe Mike a debt of gratitude for his significant
contributions to Medtronic," said Geoff
Martha, Medtronic Chairman and Chief Executive Officer.
"He's played a vital role in our Cardiovascular portfolio,
including overseeing the development and launches of numerous
disruptive and life-saving technologies. On behalf of the Board, I
would like to thank Mike for his leadership and wish him every
success."
"With 17 years leading several Medtronic business units, Sean is
a highly respected leader both inside and outside of the company,
with a proven track record of building and leading high-performing
teams. I am confident in his ability to continue the turnaround of
our Diabetes business, while ensuring continued growth and therapy
adoption in our Cardiovascular portfolio," said Martha.
Salmon joined Medtronic in 2004 and spent 15 years in
increasingly senior management roles within Cardiovascular,
including leading the Coronary and Renal Denervation, Peripheral,
Cardiac Surgery, and Structural Heart businesses, before being
named the leader of Medtronic Diabetes and a member of the
Medtronic Executive Committee in 2019. While in Cardiovascular, he
led Medtronic to leadership in drug-eluting stents, commercialized
multiple product innovations in transcatheter aortic valve
replacement (TAVR), and revitalized Medtronic's renal denervation
clinical program.
Salmon will continue his role leading the Diabetes turnaround
and his role working closely with the other portfolio leaders and
members of the Executive Committee on enterprise-level strategy and
value creation under Medtronic's new operating model. With his new
additional Cardiovascular responsibilities, Salmon will oversee the
Cardiovascular operating units, ensuring appropriate capital
allocation to optimize Medtronic's growth and profitability,
overall business performance, and innovation designed to drive
continued market expansion and increased share.
"I want to thank Geoff and the Board for this opportunity, which
allows me to have an even greater impact on improving more
patients' lives," said Salmon. "Over the past year, we've taken a
number of bold steps to improve our Diabetes performance and
competitiveness, including the appointment of a new leadership
team, accelerating R&D investment, entering the smart pen
market, and making significant progress on our customer-centric
pipeline of products and services. Completing the turnaround in
Diabetes remains a high priority for me. And, I'm excited to
reunite and work with the exceptionally talented leaders of our
Cardiovascular operating units as we continue the momentum behind
Mike's vision of growth and innovation to deliver meaningful and
life-enhancing cardiovascular technologies."
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest
medical technology, services and solutions companies – alleviating
pain, restoring health and extending life for millions of people
around the world. Medtronic employs more than 90,000 people
worldwide, serving physicians, hospitals and patients in more than
150 countries. The company is focused on collaborating with
stakeholders around the world to take healthcare Further,
Together.
Any forward-looking statements are subject to risks and
uncertainties such as those described in Medtronic's periodic
reports on file with the Securities and Exchange Commission. Actual
results may differ materially from anticipated results.
Contacts:
|
|
|
|
Marguerite
Copel
|
Ryan
Weispfenning
|
Public
Relations
|
Investor
Relations
|
+1-203-214-8243
|
+1-763-505-4626
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/sean-salmon-named-evp--president-cardiovascular-portfolio-continues-as-evp--president-diabetes-operating-unit-301192350.html
SOURCE Medtronic plc